backed Bicara Therapeutics raises $315 mln in US IPO
Adds background in paragraphs 5-9
Sept 12 (Reuters) -Bicara Therapeutics BCAX.O raised $315 million in its initial public offering in the United States, the TPG-backed TPG.Ocancer therapy developer said on Thursday.
The company priced its offering of 17.5 million shares at $18 apiece, at the high-end of its targeted range of $16 to $18 each. The IPO values Bicara at $881.4 million.
Bicara is among several drug developers that will test investor appetite with their IPOs in the coming weeks.
The company had initially planned on selling about 11.8 million shares, but Bicaraupsized the offering to 14.7 million shares on Wednesday.
Bicara's lead drug, ficerafusp alfa, is currently in an early-stage study in the U.S. to treat a type of head and neck cancer in combination with Merck'sMRK.N Keytruda.
The company plans to use part of the IPO proceeds to fund its mid-to-late stage study, which is expected to start later this year or early 2025.
Before going for its IPO, Bicara had raised $353 million in the private market, including $165 million in its last funding round co-led by alternative asset manager TPG and investment firm Braidwell.
The company is also backed by Indian drugmaker BioconBION.NS and investment manager RA Capital.
Bicara's shares are expected to start trading on the Nasdaq Global Market on Sept. 13 under the ticker symbol "BCAX".
Morgan Stanley, TD Cowen, Stifel and Cantor Fitzgerald are the underwriters for the offering.
Reporting by Gnaneshwar Rajan and Arasu Kannagi Basil in Bengaluru; Editing by Leroy Leo and Alan Barona
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
